MDRO type | Group | Se | Sp | PPV | NPV |
---|---|---|---|---|---|
ESBL | Period 1 | 62.86 (58.61–66.92) | 87.27 (84.47–89.63) | 79.85 (75.68–83.46) | 74.54 (71.31–77.52) |
Period 2 | 96.75 (94.54–98.10) | 97.55 (95.93–98.54) | 96.52 (94.24–97.92) | 97.72 (96.14–98.66) | |
Period 3 | 100 (99.03–100) | 100 (99.38–100) | 100 (99.03–100) | 100 (99.38–100) | |
MRSA | Period 1 | 80.19 (71.61–86.66) | 55.61 (48.77–62.25) | 48.30 (41.03–55.64) | 84.44 (77.38–89.59) |
Period 2 | 84.17 (76.59–89.63) | 100 (97.31–100) | 100 (96.34–100) | 87.97 (81.98–92.16) | |
Period 3 | 100 (95.47–100) | 100 (97.21–100) | 100 (95.47–100) | 100 (97.21–100) | |
CRAB | Period 1 | 74.58 (62.21–83.95) | 82.17 (74.66–87.81) | 65.67 (53.73–75-91) | 87.60 (80.55–92.34) |
Period 2 | 87.72 (76.75–93.92) | 100 (96.87–100) | 100 (92.87–100) | 94.44 (88.97–97.28) | |
Period 3 | 100 (92.59–100) | 100 (96.30–100) | 100 (92.59–100) | 100 (96.30–100) | |
CRPA | Period 1 | 56.82 (42.23–70.32) | 81.94 (77.09–85.95) | 32.47 (23.06–43.54) | 92.55 (88.66–95.18) |
Period 2 | 88.37 (75.52–94.93) | 90.48 (86.22–93.52) | 61.29 (48.85–72.42) | 97.85 (95.07–99.08) | |
Period 3 | 100 (87.13–100) | 100 (98.44–100) | 100 (87.13–100) | 100 (98.44–100) | |
CRE | Period 1 | 0 (0–11.70) | 100 (99.64–100) | 0 (0) | 97.31 (96.16–98.12) |
Period 2 | 0 (0–21.53) | 100 (99.59–100) | 0 (0) | 98.54 (97.56–99.13) | |
Period 3 | 100 (79.61–100) | 100 (99.61–100) | 100 (79.61–100) | 100 (99.61–100) |